Sign in →

Test Code THSIF Thrombospondin Type 1 Domain Containing 7A (THSD7A), Immunofluorescence


Ordering Guidance


If additional interpretation/analysis is needed, request PATHC / Pathology Consultation along with this test and send the corresponding renal pathology light microscopy and immunofluorescence (IF) slides (or IF images on a CD), electron microscopy images (prints or CD), and the pathology report.

Necessary Information


A preliminary pathology report is required for testing to be performed. Send information with specimen. The laboratory will not reject testing if a reason for testing is not provided; however appropriate testing and interpretation may be compromised or delayed. If not provided, an appropriate indication for testing may be entered by Mayo Clinic Laboratories.



Specimen Required


Specimen Type: Kidney tissue

Preferred: 2 Unstained positively charged glass slide (25- x 75- x 1-mm) per test ordered; paraffin sections 3 to 4-microns thick

Acceptable: Formalin-fixed, paraffin-embedded (FFPE) kidney tissue block


Secondary ID

605244

Useful For

Diagnosis of thrombospondin type 1 domain-containing 7A (THSD7A)-associated membranous nephropathy

Method Name

Direct Immunofluorescence (DIF)

Reporting Name

THSD7A Immunofluorescence

Specimen Type

Special

Specimen Stability Information

Specimen Type Temperature Time Special Container
Special Ambient (preferred)
  Frozen 
  Refrigerated 

Reject Due To

All specimens will be evaluated at Mayo Clinic Laboratories for test suitability.

Clinical Information

Thrombospondin type 1 domain-containing 7A (THSD7A) is a target antigen in membranous nephropathy (MN) and is detected in approximately 3% to 5% of non- phospholipase A2 receptor (PLA2R)-associated MN patients. Differentiating THSD7A-associated MN from PLA2R-associated MN is critical as approximately 20% of patients with THSD7A-associated MN have solid malignancy suggesting that THSD7A-associated MN is more likely to be secondary to malignancy than PLA2R-associated MN.

Interpretation

Staining is interpreted and reported as negative or positive.

Cautions

No significant cautionary statements

Clinical Reference

1. Hoxha E, Beck Jr LH, Wiech T et al. An indirect immunofluorescence method facilitates detection of thrombospondin type 1 domain-containing 7A-specific antibodies in membranous nephropathy. J Am Soc Nephrol. 2017;28:520-531

2. Larsen CP, Cossey LN, Bech LH. THSD7A staining of membranous glomerulopathy in clinical practice reveals cases with dual autoantibody positivity. Mod Pathol. 2016;29:421-426

3. Sharma SG, Larsen CP: Tissue staining for THSD7A in glomeruli correlates with serum antibodies in primary membranous nephropathy: a clinicopathological study. Mod Pathol. 2018;31(4):616-622

Method Description

Direct immunofluorescence staining on sections of formalin-fixed, paraffin-embedded kidney tissue.(Unpublished Mayo method)

Specimen Retention Time

Until reported

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

88346-Primary IF

88350-If additional IF

LOINC Code Information

Test ID Test Order Name Order LOINC Value
THSIF THSD7A Immunofluorescence 101116-2

 

Result ID Test Result Name Result LOINC Value
605245 Interpretation 50595-8
606383 Participated in the Interpretation No LOINC Needed
606384 Report electronically signed by 19139-5
606385 Addendum 35265-8
606386 Gross Description 22634-0
606387 Material Received 22633-2
606388 Disclaimer 62364-5
606389 Case Number 80398-1

Forms

If not ordering electronically, complete, print, and send a Renal Diagnostics Test Request (T830) with the specimen.

Specimen Minimum Volume

See Specimen Required

Day(s) Performed

Monday through Friday

Report Available

1 to 2 days